Dr. Alexander Perl is a member of the leukemia program at the Abramson Cancer Center of the University of Pennsylvania, where he is an Associate Professor of Medicine. His particular expertise is in FLT3 inhibition as a therapeutic strategy for acute myeloid leukemia, clinical trials, and mechanisms of resistance to tyrosine kinase inhibitors.